M&A Deal Summary |
|
---|---|
Date | 2024-10-07 |
Target | AltarBio |
Sector | Life Science |
Buyer(s) | Lesaffre et Compagnie SA |
Sellers(s) | Ginkgo Bioworks |
Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
Lesaffre et Compagnie SA is a provider in the field of yeast and fermentation products.
DEAL STATS | # |
---|---|
Overall | 7 of 7 |
Sector (Life Science) | 3 of 3 |
Type (Divestiture) | 1 of 1 |
Country (France) | 1 of 1 |
Year (2024) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2022-09-07 |
Recombia Biosciences
Brisbane, California, United States Recombia Biosciences is based on technologies for enhanced high throughput genome editing and synthetic biology and will use these technologies to discover ways in which industrial strains of yeast can be improved for manufacturing different products. Recombia Biosciences was founded in 2019 and is based in Brisbane, California. |
Buy | - |
Category | Company |
---|---|
Founded | 2008 |
Sector | Life Science |
Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks was established in 2008 and is based in Boston, Massachusetts.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
Country (France) | 1 of 1 |
Year (2024) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2024-04-02 |
Modulus Therapeutics - Cell Therapy Assets
Seattle, Washington, United States Modulus Therapeutics' Cell Therapy Assets provides chimeric antigen receptor (CAR) and switch receptor libraries. |
Buy | - |